OGM Adoption Target hematological malignancy centers and cancer governance bodies with Lineagen’s OGM-based LDT offerings like HemeOne and Category I CPT code strategy to position as a complementary diagnostic layer for SV detection and prognosis.

Clinical Expansion Leverage recent LDT launches and Category I CPT code availability to approach hospital systems and reference labs seeking expanded genetic testing menus, emphasizing faster access to SV-focused insights via optical genome mapping.

Tech Enablement Highlight compatibility with established platforms (OGM workflows) and cloud-based data analysis to appeal to labs modernizing their infrastructure, while offering scalable support through Google Cloud Platform and current tech stack.

Strategic Partnerships Position Lineagen as a niche partner for mid-to-large molecular labs and regional health systems that need specialized SV detection, offering joint development of diagnostic assays and integration into existing lab workflows.

Growth Signals Capitalize on private funding and solid revenue indicators to approach potential acquirers or collaborators in the diagnostic space, emphasizing a growing portfolio of LDTs and a proven path to CPT coding and reimbursement.